Prostate cancer is a common occurrence in the aging population, with one in ten men destined
to develop the disease. 40% of patients with prostate cancer experience a recurrence after
definitive treatment. This study addresses the as-yet unresolved problem of the optimal
management of early recurrence as manifested by increase in the accepted marker for this
disease, PSA. Vitamin D, an agent with cell-differentiating properties, has been shown to
inhibit angiogenesis and cause differentiation of prostate cancer cells in the laboratory
and to affect PSA favorably in clinical studies of patients with advanced prostate cancer.
This study will assess the effects of vitamin D in patients with sub-clinical biochemical
relapses of prostate cancer as indicated by rising PSA but low tumor burdens, with the
potential for developing an approach to this problem that will delay or prevent progression.
Patients will be males with three successive rises in PSA after achieving a nadir
post-definitive therapy. The following criteria must be met: pathologically confirmed
prostate cancer, completion of definitive treatment in the form of local external beam
radiation or definitive surgery and three successive rises in PSA with no clinical
evidence of disease.